Connection

Susan Dorman to Humans

Back to Details
This is a "connection" page, showing publications Susan Dorman has written about Humans.
Susan Dorman
Connection Strength
1.148
Humans
  1. Latent Tuberculosis Infection. Reply. N Engl J Med. 2022 03 31; 386(13):e33.
    View in: PubMed
    Score: 0.031
  2. Four-Month Rifapentine Regimens for Tuberculosis. Reply. N Engl J Med. 2022 03 17; 386(11):1095-1096.
    View in: PubMed
    Score: 0.031
  3. Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. BMC Infect Dis. 2022 Mar 12; 22(1):246.
    View in: PubMed
    Score: 0.031
  4. Latent Tuberculosis Infection. N Engl J Med. 2021 12 09; 385(24):2271-2280.
    View in: PubMed
    Score: 0.031
  5. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
    View in: PubMed
    Score: 0.029
  6. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 03; 90:105938.
    View in: PubMed
    Score: 0.027
  7. Transmission of Mycobacterium tuberculosis From Patients Who Are Nucleic Acid Amplification Test Negative. Clin Infect Dis. 2018 11 13; 67(11):1653-1659.
    View in: PubMed
    Score: 0.025
  8. Diagnosis of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2018 11; 13(6):462-468.
    View in: PubMed
    Score: 0.025
  9. Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 2017 12 14; 377(24):2404.
    View in: PubMed
    Score: 0.023
  10. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018 01; 18(1):76-84.
    View in: PubMed
    Score: 0.023
  11. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One. 2016; 11(5):e0154778.
    View in: PubMed
    Score: 0.021
  12. Analytical and Clinical Evaluation of the Epistem Genedrive Assay for Detection of Mycobacterium tuberculosis. J Clin Microbiol. 2016 Apr; 54(4):1051-7.
    View in: PubMed
    Score: 0.020
  13. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015 Jul; 19(7):780-6.
    View in: PubMed
    Score: 0.020
  14. Advances in the diagnosis of tuberculosis: current status and future prospects. Int J Tuberc Lung Dis. 2015 May; 19(5):504-16.
    View in: PubMed
    Score: 0.019
  15. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015 Feb 01; 191(3):333-43.
    View in: PubMed
    Score: 0.019
  16. Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda. PLoS One. 2014; 9(7):e101459.
    View in: PubMed
    Score: 0.018
  17. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014 Jul 01; 66(3):270-9.
    View in: PubMed
    Score: 0.018
  18. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS. 2014 Jun 01; 28(9):1307-14.
    View in: PubMed
    Score: 0.018
  19. Prospective cross-sectional evaluation of the small membrane filtration method for diagnosis of pulmonary tuberculosis. J Clin Microbiol. 2014 Jul; 52(7):2513-20.
    View in: PubMed
    Score: 0.018
  20. Interferon-? release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014 Jan 01; 189(1):77-87.
    View in: PubMed
    Score: 0.018
  21. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda. AIDS. 2013 Nov 28; 27(18):2883-92.
    View in: PubMed
    Score: 0.018
  22. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infect Dis. 2013 Jul 29; 13:352.
    View in: PubMed
    Score: 0.017
  23. QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. BMC Infect Dis. 2012 Dec 19; 12:360.
    View in: PubMed
    Score: 0.016
  24. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One. 2012; 7(8):e43307.
    View in: PubMed
    Score: 0.016
  25. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012 Oct 01; 206(7):1030-40.
    View in: PubMed
    Score: 0.016
  26. Programmatic impact of QuantiFERON-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic. PLoS One. 2012; 7(5):e36551.
    View in: PubMed
    Score: 0.016
  27. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012 May; 91(5):881-8.
    View in: PubMed
    Score: 0.016
  28. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol. 2012 Apr; 50(4):1189-94.
    View in: PubMed
    Score: 0.015
  29. Longitudinal analysis of QuantiFERON-TB Gold In-Tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study. PLoS One. 2011; 6(10):e26787.
    View in: PubMed
    Score: 0.015
  30. QuantiFERON-TB Gold In-Tube for the detection of Mycobacterium tuberculosis infection in children with household tuberculosis contact. Int J Tuberc Lung Dis. 2011 May; 15(5):628-34.
    View in: PubMed
    Score: 0.015
  31. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol. 2010 Aug; 48(8):2972-4.
    View in: PubMed
    Score: 0.014
  32. New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S173-7.
    View in: PubMed
    Score: 0.014
  33. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant. 2009 Dec; 9 Suppl 4:S63-9.
    View in: PubMed
    Score: 0.013
  34. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009 Aug 01; 180(3):273-80.
    View in: PubMed
    Score: 0.013
  35. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis. 2009 Feb 28; 9:23.
    View in: PubMed
    Score: 0.013
  36. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One. 2008; 3(12):e4057.
    View in: PubMed
    Score: 0.012
  37. Cost-effectiveness of different strategies for amplified Mycobacterium tuberculosis direct testing for cases of pulmonary tuberculosis. J Clin Microbiol. 2008 Nov; 46(11):3811-2.
    View in: PubMed
    Score: 0.012
  38. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother. 2008 Nov; 52(11):4037-42.
    View in: PubMed
    Score: 0.012
  39. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A. 2008 Aug 12; 105(32):11293-8.
    View in: PubMed
    Score: 0.012
  40. Timing of therapy for latent tuberculosis infection among immigrants presenting to a U.S. public health clinic: a retrospective study. BMC Public Health. 2008 May 12; 8:158.
    View in: PubMed
    Score: 0.012
  41. Lymphadenitis in an 18-month-old traveler to Mexico. Pediatr Infect Dis J. 2007 Oct; 26(10):968, 973-4.
    View in: PubMed
    Score: 0.011
  42. Clinical evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to isoniazid or rifampin. J Clin Microbiol. 2007 Oct; 45(10):3387-9.
    View in: PubMed
    Score: 0.011
  43. Use of the amplified mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care. Chest. 2007 Sep; 132(3):946-51.
    View in: PubMed
    Score: 0.011
  44. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med. 2007 Mar; 13(3):295-8.
    View in: PubMed
    Score: 0.011
  45. Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis. Clin Infect Dis. 2007 Mar 01; 44(5):674-80.
    View in: PubMed
    Score: 0.011
  46. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006 Sep 25; 166(17):1863-70.
    View in: PubMed
    Score: 0.011
  47. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS. 2006 Mar 21; 20(5):751-62.
    View in: PubMed
    Score: 0.010
  48. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet. 2004 Dec 11-17; 364(9451):2113-21.
    View in: PubMed
    Score: 0.009
  49. Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol. 2004 Feb; 6(2):105-16.
    View in: PubMed
    Score: 0.009
  50. Immunoglobulin A (IgA) and IgG immune responses against P-90 antigen for diagnosis of pulmonary tuberculosis and screening for Mycobacterium tuberculosis infection. Clin Diagn Lab Immunol. 2004 Jan; 11(1):94-7.
    View in: PubMed
    Score: 0.009
  51. Cost-effectiveness analysis of the gen-probe amplified mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. J Clin Microbiol. 2003 Mar; 41(3):948-53.
    View in: PubMed
    Score: 0.008
  52. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
    View in: PubMed
    Score: 0.008
  53. Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection. Respir Med. 2023 01; 206:107069.
    View in: PubMed
    Score: 0.008
  54. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV. 2022 11; 9(11):e791-e800.
    View in: PubMed
    Score: 0.008
  55. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022 09 10; 75(4):560-566.
    View in: PubMed
    Score: 0.008
  56. Field evaluation of a rapid immunochromatographic test for tuberculosis. J Clin Microbiol. 2002 Jun; 40(6):1989-93.
    View in: PubMed
    Score: 0.008
  57. Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. Am J Respir Crit Care Med. 2022 05 15; 205(10):1228-1235.
    View in: PubMed
    Score: 0.008
  58. Chest Computed Tomography Features of Nontuberculous Mycobacterial Pulmonary Disease Versus Asymptomatic Colonization: A Cross-sectional Cohort Study. J Thorac Imaging. 2022 May 01; 37(3):140-145.
    View in: PubMed
    Score: 0.007
  59. Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2021 09 17; 65(10):e0179420.
    View in: PubMed
    Score: 0.007
  60. Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. J Antimicrob Chemother. 2021 02 11; 76(3):582-586.
    View in: PubMed
    Score: 0.007
  61. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2020 09 15; 202(6):866-877.
    View in: PubMed
    Score: 0.007
  62. Multicenter Study of the Accuracy of the BD MAX Multidrug-resistant Tuberculosis Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated With Resistance to Rifampin and Isoniazid. Clin Infect Dis. 2020 08 22; 71(5):1161-1167.
    View in: PubMed
    Score: 0.007
  63. Predictive value of TNF-a, IFN-?, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. BMC Infect Dis. 2020 Jul 31; 20(1):553.
    View in: PubMed
    Score: 0.007
  64. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. Lancet Infect Dis. 2020 06; 20(6):742-752.
    View in: PubMed
    Score: 0.007
  65. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. Lancet HIV. 2020 01; 7(1):e27-e37.
    View in: PubMed
    Score: 0.007
  66. Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. J Infect Dis. 2019 10 08; 220(220 Suppl 3):S99-S107.
    View in: PubMed
    Score: 0.007
  67. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrob Agents Chemother. 2019 04; 63(4).
    View in: PubMed
    Score: 0.006
  68. Adjunctive corticosteroid therapy for patients whose treatment for disseminated Mycobacterium avium complex infection has failed. Clin Infect Dis. 1998 Mar; 26(3):682-6.
    View in: PubMed
    Score: 0.006
  69. Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study. Int J Infect Dis. 2018 Mar; 68:44-49.
    View in: PubMed
    Score: 0.006
  70. Serologic Responses in Childhood Pulmonary Tuberculosis. Pediatr Infect Dis J. 2018 Jan; 37(1):1-9.
    View in: PubMed
    Score: 0.006
  71. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 2017 09 14; 377(11):1043-1054.
    View in: PubMed
    Score: 0.006
  72. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017 Aug; 102(2):321-331.
    View in: PubMed
    Score: 0.005
  73. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat Genet. 2017 Mar; 49(3):395-402.
    View in: PubMed
    Score: 0.005
  74. Reply to Alffenaar et al. Clin Infect Dis. 2017 01 01; 64(1):105-106.
    View in: PubMed
    Score: 0.005
  75. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 10 01; 63(7):853-67.
    View in: PubMed
    Score: 0.005
  76. Comparing TSPOT assay results between an Elispot reader and manual counts. Tuberculosis (Edinb). 2016 12; 101S:S92-S98.
    View in: PubMed
    Score: 0.005
  77. Differential positive TSPOT assay responses to ESAT-6 and CFP-10 in health care workers. Tuberculosis (Edinb). 2016 12; 101S:S83-S91.
    View in: PubMed
    Score: 0.005
  78. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 10 01; 63(7):e147-e195.
    View in: PubMed
    Score: 0.005
  79. Occupational Risk Factors for Tuberculosis Among Healthcare Workers in KwaZulu-Natal, South Africa. Clin Infect Dis. 2016 05 15; 62 Suppl 3:S255-61.
    View in: PubMed
    Score: 0.005
  80. Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology. PLoS One. 2015; 10(7):e0133756.
    View in: PubMed
    Score: 0.005
  81. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015; 59(6):3399-405.
    View in: PubMed
    Score: 0.005
  82. Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. Trials. 2015 Mar 28; 16:125.
    View in: PubMed
    Score: 0.005
  83. Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda. BMC Infect Dis. 2015 Feb 15; 15:62.
    View in: PubMed
    Score: 0.005
  84. Improving the sensitivity of the Xpert MTB/RIF assay on sputum pellets by decreasing the amount of added sample reagent: a laboratory and clinical evaluation. J Clin Microbiol. 2015 Apr; 53(4):1258-63.
    View in: PubMed
    Score: 0.005
  85. Clinical utility of a novel molecular assay in various combination strategies with existing methods for diagnosis of HIV-related tuberculosis in Uganda. PLoS One. 2014; 9(9):e107595.
    View in: PubMed
    Score: 0.005
  86. Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis. Antimicrob Agents Chemother. 2014 Nov; 58(11):6747-57.
    View in: PubMed
    Score: 0.005
  87. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014 Jun; 58(6):3035-42.
    View in: PubMed
    Score: 0.004
  88. Cost-effectiveness of routine diagnostic evaluation of pulmonary tuberculosis in a primary care unit in Brazil. Int J Tuberc Lung Dis. 2013 Oct; 17(10):1336-40.
    View in: PubMed
    Score: 0.004
  89. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013 Sep 03; 13:407.
    View in: PubMed
    Score: 0.004
  90. The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States. Clin Infect Dis. 2013 Aug; 57(4):532-42.
    View in: PubMed
    Score: 0.004
  91. Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults. Int J Tuberc Lung Dis. 2013 Apr; 17(4):552-8.
    View in: PubMed
    Score: 0.004
  92. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study. PLoS One. 2012; 7(11):e49898.
    View in: PubMed
    Score: 0.004
  93. A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa. Int J Tuberc Lung Dis. 2012 Jan; 16(1):82-9.
    View in: PubMed
    Score: 0.004
  94. Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr. 2011 Oct 01; 58(2):219-23.
    View in: PubMed
    Score: 0.004
  95. Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One. 2011 Apr 11; 6(4):e18358.
    View in: PubMed
    Score: 0.004
  96. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant. 2009 Dec; 9 Suppl 4:S57-62.
    View in: PubMed
    Score: 0.003
  97. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr. 2009 Oct 01; 52(2):145-51.
    View in: PubMed
    Score: 0.003
  98. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009 Apr; 80(4):634-9.
    View in: PubMed
    Score: 0.003
  99. Specimen dilution improves sensitivity of the amplified Mycobacterium tuberculosis direct test for smear microscopy-positive respiratory specimens. J Clin Microbiol. 2008 Jan; 46(1):314-6.
    View in: PubMed
    Score: 0.003
  100. Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury. Int J Tuberc Lung Dis. 2007 Jul; 11(7):775-80.
    View in: PubMed
    Score: 0.003
  101. A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol. 2004 Sep 15; 173(6):4000-8.
    View in: PubMed
    Score: 0.002
  102. Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits. Infect Immun. 2004 Mar; 72(3):1700-5.
    View in: PubMed
    Score: 0.002
  103. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med. 2003 Nov 13; 349(20):1977-8.
    View in: PubMed
    Score: 0.002
  104. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 01; 37(11):1448-52.
    View in: PubMed
    Score: 0.002
  105. Nocardia veterana as a pathogen in North American patients. J Clin Microbiol. 2003 Jun; 41(6):2560-8.
    View in: PubMed
    Score: 0.002
  106. Isolated intracranial infection with Mycobacterium avium complex. J Neurosurg Sci. 2003 Jun; 47(2):101-5; discussion 105.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.